Discover and read the best of Twitter Threads about #backtoheart21
Most recents (2)
Session IV of #BacktoHeart21 covering all things cardiometabolic disease occuring now!
First up, @JJheart_doc discusses SGLTI2 for T2DM and ASCVD!
@MedscapeLIVE
First up, @JJheart_doc discusses SGLTI2 for T2DM and ASCVD!
@MedscapeLIVE
Next up @busediabetes discusses GLP-1 agonists in patients with T2DM and ASVCD!
Dr. Darren McGuire discusses hypoglycemia and adverse outcomes.
> Hypoglycemia associated with higher risk of MACE and mortality
> Adverse outcomes may be reflective of frailty/disease severity rather than causal
> Hypoglycemia associated with higher risk of MACE and mortality
> Adverse outcomes may be reflective of frailty/disease severity rather than causal
Session 3 of #BacktoHeart21 happening now and covering #Lipids moderated by @FaRodriguezMD @PamelaBMorris & @DLBHATTMD!
First up @alanbrownmd covers COVID-19 and statin therapy! Promising observational data and many RCTs ongoing!
@MedscapeLIVE
First up @alanbrownmd covers COVID-19 and statin therapy! Promising observational data and many RCTs ongoing!
@MedscapeLIVE
@FaRodriguezMD @PamelaBMorris @DLBHATTMD @alanbrownmd @MedscapeLIVE Next up @PamelaBMorris discusses lipid lowering beyond statins!
More data to come for bempedoic acid, Evinacumab, and Inclisiran! Lots of options emerging for LDL lowering
More data to come for bempedoic acid, Evinacumab, and Inclisiran! Lots of options emerging for LDL lowering
@FaRodriguezMD @PamelaBMorris @DLBHATTMD @alanbrownmd @MedscapeLIVE @DrRSRosenson provides a expert review of HIV and ischemic heart disease!
> HIV patients have high rates of CV events
> Lipid lowering therapy are underutilized
> 1/4 patients are treated with contraindicated statins or doses
> HIV patients have high rates of CV events
> Lipid lowering therapy are underutilized
> 1/4 patients are treated with contraindicated statins or doses
